• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering
  • Home
  • $
  • Press Releases & Media
  • $
  • Press Releases

Press Releases

Press Releases

menu tendinaNEWS
menu tendinaNEWS-scientific/investors
21 May 2026

Deposito del Verbale dell’Assemblea degli Azionisti

More details

Read more
12 May 2026

Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026

more details

Read more
12 May 2026

The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)

more detalis

Read more
29 April 2026

L’Assemblea degli Azionisti di Philogen S.p.A. ha approvato il bilancio 2025

more details

Read more
8 April 2026

Avviso di pubblicazione della documentazione relativa all’Assemblea degli Azionisti convocata per il 29 aprile 2026

more details

Read more
30 March 2026

Avviso di pubblicazione della documentazione relativa all’Assemblea degli Azionisti convocata per il 29 aprile 2026

more details

Read more
27 March 2026

Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio e il bilancio consolidato al 31 dicembre 2025 (Price sensitive)

more details

Read more
  • Next »

Privacy Policy / Cookie Policy

  Contacts

  • Follow
  • Follow

Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it